# A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

> **NCT06508983** · PHASE3 · RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** SG301 Injection
- **DRUG:** SG301 placebo
- **DRUG:** pomalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT06508983
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-14
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508983, "A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06508983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*